Drug intelligence / Profile preview

celecoxib + ursodeoxycholic acid

Development stage: Discontinued
Lead developer: Radboud University Medical Center
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of the selective COX-2 inhibitor celecoxib and the naturally occurring bile acid ursodeoxycholic acid (UDCA). This specific combination was investigated by Radboud University Medical Center in a Phase 2/3 clinical trial (NCT00808743) for the chemoprevention of duodenal adenomatosis in patients with Familial Adenomatous Polyposis (FAP). The rationale was to modulate bile acid composition and inhibit inflammatory pathways to prevent the progression of adenomas to carcinomas. However, the trial results indicated that UDCA might have counteracted the beneficial effects of celecoxib, leading to no significant improvement in polyp density.

Other names: UDCA + celecoxibursodeoxycholic acid + celecoxibUDCAursodiol

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GPBAR1FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on celecoxib + ursodeoxycholic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on celecoxib + ursodeoxycholic acid.

Explore the full profile